Safety of iron polymaltose given as a total dose iron infusion.

Abstract

An audit of the in-hospital safety and tolerability of 401 infusions of iron polymaltose in 386 patients has shown no cases of anaphylaxis or other cardiorespiratory compromise. The infusion was terminated prematurely because of adverse events in six patients (1.6%). No adverse events occurred within the first 15 min of the infusion. Premedication (in 24%) was not associated with fewer adverse events. Fear of anaphylaxis should not inhibit the use of total dose iron infusion and the practices of premedication and of medical supervision during the first 15 min of the infusion should be abandoned.

• Authors: E Newnham, I Ahmad, A Thornton, P R Gibson
• Journal: Internal medicine journal (Intern Med J) Vol. 36 Issue 10 Pg. 672-4 (Oct 2006) ISSN: 1445-5994 [Electronic] Australia
• PMID: 16958647 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Iron

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anemia, Iron-Deficiency (drug therapy, epidemiology)
• Exanthema (chemically induced, epidemiology)
• Female
• Humans
• Infusions, Intravenous
• Iron (administration & dosage, adverse effects)
• Male
• Middle Aged
• Nausea (chemically induced, epidemiology)
• Retrospective Studies